國家衛生研究院 NHRI:Item 3990099045/7472
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 913431      Online Users : 1141
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7472


    Title: Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
    Authors: Finn, RS;Poon, RTP;Yau, T;Klümpen, HJ;Chen, LT;Kang, YK;Kim, TY;Gomez-Martin, C;Rodriguez-Lope, C;Kunz, T;Paquet, T;Brandt, U;Sellami, D;Bruix, J
    Contributors: National Institute of Cancer Research
    Abstract: Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC). Combination therapy targeting multiple signaling pathways may improve outcomes. This phase I study was designed to determine the maximum tolerated dose (MTD) of everolimus given with sorafenib 400 mg twice daily in patients with advanced HCC of Child-Pugh class A liver function who were naive to systemic therapy. Methods Everolimus was initiated at 2.5 mg once daily and increased per a Bayesian sequential dose-escalation scheme based on the dose-limiting toxicities experienced within the first 28 days of treatment. Adverse events were assessed continuously. Efficacy was evaluated using the best overall response rate per RECIST. Results Thirty patients were enrolled; 25 were evaluable for MTD determination. One of 12 patients treated with everolimus 2.5 mg once daily and 6 of 13 patients treated with everolimus 5.0 mg once daily experienced a dose-limiting toxicity, most commonly thrombocytopenia (n=5). All patients experienced ⩾1 adverse event, most commonly diarrhea (66.7%), hand-foot skin reaction (66.7%), and thrombocytopenia (50.0%). Best overall response was stable disease (62.5% and 42.9% in the 2.5-mg and 5.0-mg cohorts, respectively). Median time to progression and overall survival in the 2.5-mg cohort were 4.5 months and 7.4 months, respectively, and 1.8 months and 11.7 months, respectively, in the 5.0-mg cohort. Conclusions In patients with advanced HCC, the everolimus MTD in combination with standard-dose sorafenib was 2.5 mg once daily. The inability to achieve a biologically effective everolimus concentration at the MTD precluded phase II study of this combination.
    Date: 2013-12
    Relation: Journal of Hepatology. 2013 Dec;59(6):1271-1277.
    Link to: http://dx.doi.org/10.1016/j.jhep.2013.07.029
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0168-8278&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000327141800018
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84887993101
    Appears in Collections:[Li-Tzong Chen] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    SDO0168827813005448.pdf594KbAdobe PDF495View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback